Form 4: Cullinan Therapeutics CEO Nadim Ahmed Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Cullinan Therapeutics' CEO, Nadim Ahmed, sold 12,529 shares of common stock on February 25, 2025, to cover personal income tax obligations arising from the vesting of restricted stock units.
Summary
- On February 25, 2025, Nadim Ahmed, the President and CEO of Cullinan Therapeutics, Inc. (CGEM), sold 12,529 shares of the company's common stock.
- The sale was executed at a price of $8.53 per share.
- The transaction was conducted to cover personal income tax obligations related to the vesting of restricted stock units.
- Following the transaction, Ahmed directly owns 430,621 shares of Cullinan Therapeutics' common stock.
Sentiment
Score: 6
Explanation: The document reflects a neutral event (stock sale for tax purposes) and doesn't suggest any positive or negative sentiment towards the company's prospects.
Industry Context
Sales of shares to cover tax obligations are a common practice among executives who receive equity compensation. This transaction is a routine part of executive compensation and doesn't necessarily indicate a change in the executive's confidence in the company.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the stated reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of the stock sale transaction. |
| 02/27/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.